Risultati per: Diagnosi e trattamento della cardiomiopatia ipertrofica (HCM)

La gran parte degli accessi al PS legata ai sintomi del cancro

Circulation, Volume 150, Issue 19, Page 1560-1562, November 5, 2024.

E’ il “Fibroscan”, per individuare patologie croniche

E’ il “Fibroscan”, per individuare patologie croniche

Medici e pazienti, ‘più formazione e rendere le terapie disponibili per tutti’

Non solo un problema dei bimbi ma “attenzione all’autodiagnosi”

Introduction
Atrial fibrillation (AF) is an independent predictor of adverse outcomes in patients with hypertrophic cardiomyopathy (HCM). Although catheter ablation is highly recommended for general AF populations, it is less effective in maintaining sinus rhythm in patients with HCM associated with AF. Hybrid ablation, combining a cosmetic approach with a lower rate of AF relapse, lacks comparative studies to verify its efficacy against CA in HCM. This study aims to assess the rhythm control effectiveness of hybrid versus CA in non-obstructive HCM (non-oHCM) patients with AF.

Methods/analysis
This prospective, multicentre, randomised trial involves a blinded assessment of outcomes in non-oHCM patients with non-paroxysmal AF. Sixty-six candidates from three centres will be randomised 1:1 to either hybrid or CA, including isthmus addressed lesion sets. Participants will be stratified by left atrial (LA) size (LA diameter ≤50 mm or >50 mm). Follow-ups at the 3rd, 6th and 12th months will evaluate the primary endpoint of freedom from documented atrial tachycardia lasting over 30 s within 12 months post-procedure without antiarrhythmic drugs, along with secondary endpoints of all-cause mortality, cardiovascular-related mortality, cerebral stroke, peripheral vascular embolism, heart failure-related rehospitalisation, all-cause rehospitalisation and quality of life assessments.

Ethics and disseminationapproval
The central ethics committee at Fuwai Hospital has approved the Hypertrophic CardioMyopathy with Atrial Fibrillation trial (approval number: 2022-1736). Results will be disseminated through publications in peer-reviewed journals and presentations at conferences.

Trial registration number
NCT05610215.

Per l’86% degli oncologi sono troppe le disparità di accesso alle cure